贝利尤单抗联合硫唑嘌呤在ANCA相关血管炎维持缓解中的疗效与安全性:随机对照研究
这项多中心双盲安慰剂对照研究纳入105例ANCA相关血管炎(AAV)患者,在利妥昔单抗或环磷酰胺诱导缓解后,随机接受贝利尤单抗或安慰剂联合硫唑嘌呤和低剂量糖皮质激素维持治疗。结果显示贝利尤单抗未降低首次方案指定事件(PSE)或血管炎复发风险,不良事件发生率与安慰剂组相近,无新安全性信号。
要点
- 贝利尤单抗联合硫唑嘌呤和激素未降低AAV维持期PSE风险(校正HR 1.07,95%CI 0.44-2.59;P=0.884)。
- 贝利尤单抗未降低血管炎复发风险(校正HR 0.88,95%CI 0.29-2.65;P=0.821)。
- 贝利尤单抗组所有复发(n=6)均见于PR3-ANCA阳性且环磷酰胺诱导缓解者。
核心结论
- 贝利尤单抗联合硫唑嘌呤和糖皮质激素用于AAV维持缓解未降低复发风险。
研究设计与样本
- 多中心、双盲、安慰剂对照研究,纳入105例年龄≥18岁的AAV患者,按1:1随机接受贝利尤单抗(10 mg/kg)或安慰剂,联合硫唑嘌呤(2 mg/kg/天)和低剂量口服糖皮质激素(≤10 mg/天)。
- 患者均在利妥昔单抗或环磷酰胺联合糖皮质激素诱导缓解后入组;因治疗实践变化,研究人群从约300例缩减至约100例。
主要发现
- 贝利尤单抗组53例(PR3-ANCA 41例,MPO-ANCA 12例),安慰剂组52例(PR3-ANCA 40例,MPO-ANCA 12例);基线时27例为利妥昔单抗诱导缓解,78例为环磷酰胺诱导缓解。
- 贝利尤单抗组PSE发生10例(18.9%),安慰剂组11例(21.2%);校正HR 1.07(95%CI 0.44-2.59;P=0.884)。
- 贝利尤单抗组血管炎复发6例,安慰剂组8例;校正HR 0.88(95%CI 0.29-2.65;P=0.821)。
- 安慰剂组复发(n=8)与诱导方案、疾病分期或ANCA类型无关;贝利尤单抗组所有复发(n=6)均发生于PR3-ANCA阳性且环磷酰胺诱导缓解的患者。
- 不良事件发生率:贝利尤单抗组49/53(92.5%),安慰剂组43/52(82.7%),无新安全性问题。
关键数值与推荐
- 主要终点为首次方案指定事件(PSE)时间,PSE定义为BVAS≥6分、存在≥1项主要BVAS条目或因任何原因使用禁用药物导致治疗失败。
- 血管炎复发定义为PSE为BVAS活动评分≥6分或因血管炎使用禁用药物。
- PSE风险校正因素包括ANCA类型(PR3或MPO)、诱导期疾病分期和诱导方案。
临床怎么用
- 对于经利妥昔单抗或环磷酰胺诱导缓解的AAV患者,贝利尤单抗联合硫唑嘌呤和激素未显示降低复发风险,不支持该方案用于维持缓解以减少复发。
局限性
- 研究因治疗实践变化导致样本量从约300例缩减至约100例,可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of belimumab as adjunctive therapy to maintain remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). METHODS: In this multicenter, double-blind, placebo-controlled study, patients with AAV (ages ≥18 years) were randomized 1:1 to receive azathioprine (2 mg/kg/day), low-dose oral glucocorticoids (≤10 mg/day), and either intravenous belimumab (10 mg/kg) or placebo, following remission induction with rituximab or cyclophosphamide along with glucocorticoids. The primary end point was time to first protocol-specified event (PSE), with first PSE defined as a Birmingham Vasculitis Activity Score (BVAS) of ≥6, presence of ≥1 major BVAS item, or receipt of prohibited medications for any reason, resulting in treatment failure (adjusted for ANCA type [proteinase 3 (PR3) or myeloperoxidase (MPO)], disease stage at induction, and induction regimen). Vasculitis relapse was defined as the PSE of either a BVAS activity score of ≥6 or receipt of prohibited medications for vasculitis. Changes in treatment practice led to truncation of the study population from ~300 patients to ~100 patients. RESULTS: The intent-to-treat population totaled 105 patients with AAV, of whom 52 (40 with PR3-ANCAs, 12 with MPO-ANCAs) received placebo and 53 (41 with PR3-ANCAs, 12 with MPO-ANCAs) received belimumab; 27 of the patients were in rituximab-induced disease remission, while 78 were in cyclophosphamide-induced disease remission at baseline. Compared with placebo, treatment with belimumab did not reduce the risk of a PSE (adjusted hazard ratio [HR] 1.07, 95% confidence interval [95% CI] 0.44-2.59; P = 0.884) or vasculitis relapse (adjusted HR 0.88, 95% CI 0.29-2.65; P = 0.821). The overall rate of PSEs was low (11 [21.2%] of 52 patients receiving placebo, 10 [18.9%] of 53 patients receiving belimumab). Vasculitis relapse in the placebo group (n = 8) occurred independent of the induction regimen, disease stage, or ANCA type. All vasculitis relapses in the belimumab group (n = 6) occurred in patients who had PR3-ANCA-associated vasculitis with cyclophosphamide-induced disease remission. Adverse events occurred in 49 (92.5%) of 53 patients receiving belimumab and 43 (82.7%) of 52 patients receiving placebo, with no new safety concerns. CONCLUSION: Belimumab plus azathioprine and glucocorticoids for the maintenance of remission in AAV did not reduce the risk of relapse.
引用
- Jayne D, Blockmans D, Luqmani R, et al. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Arthritis Rheumatol. 2019. PMID: 30666823. doi:10.1002/art.40802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。